<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00343668</url>
  </required_header>
  <id_info>
    <org_study_id>KCSG-ST05-02</org_study_id>
    <nct_id>NCT00343668</nct_id>
  </id_info>
  <brief_title>S-1 and Irinotecan Combination Chemotherapy for Advanced Gastric Cancer</brief_title>
  <official_title>A Phase II Study of S-1 and Irinotecan Combination Chemotherapy in Patients With Advanced Gastric Cancer as a First-Line Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korean Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korean Cancer Study Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this phase II trial is to evaluate the response rate of combination&#xD;
      chemotherapy with S-1 and Irinotecan in patients with advanced gastric cancer as a first-line&#xD;
      therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2005</start_date>
  <completion_date type="Anticipated">July 2008</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response rate</measure>
    <time_frame>best response</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>treatment-related toxicities</measure>
    <time_frame>during treatment</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Gastric Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1, irinotecan</intervention_name>
    <description>S-1, 40 mg/m2 PO twice daily, days 1-14 irinotecan, 150 mg/m2 IV, day 1</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically proven unresectable adenocarcinoma of stomach&#xD;
&#xD;
          -  With uni-dimensionally measurable disease (at least longest diameter 2 cm on&#xD;
             conventional CT scan, x-ray or physical examination, or 1cm on spiral CT scan)&#xD;
&#xD;
          -  Age 18 to 70 years old&#xD;
&#xD;
          -  Estimated life expectancy of more than 3 months&#xD;
&#xD;
          -  ECOG performance status of 2 or lower&#xD;
&#xD;
          -  Adequate bone marrow function(absolute neutrophil count [ANC] ≥1,500/µL, hemoglobin&#xD;
             ≥9.0 g/dL,and platelets ≥100,000/µL)&#xD;
&#xD;
          -  Adequate kidney function (serum creatinine &lt; 1.5 mg/dL)&#xD;
&#xD;
          -  Adequate liver function (serum total bilirubin &lt; 2 times the upper normal limit (UNL);&#xD;
             serum transaminases levels &lt;3 times [&lt;5 times for patients with liver metastasis] UNL)&#xD;
&#xD;
          -  No prior chemotherapy but prior adjuvant chemotherapy finished at least 6 months&#xD;
             before enrollment was allowed. (but, prior adjuvant chemotherapy with capecitabine or&#xD;
             S-1 or camptothecin analogues was excluded)&#xD;
&#xD;
          -  No prior radiation therapy for at least 4 weeks before enrollment in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other tumor type than adenocarcinoma&#xD;
&#xD;
          -  Central nervous system (CNS) metastases or prior radiation for CNS metastases&#xD;
&#xD;
          -  Gastric outlet obstruction or intestinal obstruction&#xD;
&#xD;
          -  Evidence of gastrointestinal bleeding&#xD;
&#xD;
          -  The patient has bony lesions as the sole evaluable disease.&#xD;
&#xD;
          -  Past or concurrent history of neoplasm other than stomach cancer, except for&#xD;
             curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix uteri&#xD;
&#xD;
          -  Pregnant or lactating women, women of childbearing potential not employing adequate&#xD;
             contraception&#xD;
&#xD;
          -  Other serious illness or medical conditions&#xD;
&#xD;
               -  Unstable cardiac disease despite treatment, myocardial infarction within 6 months&#xD;
                  prior to study entry&#xD;
&#xD;
               -  History of significant neurologic or psychiatric disorders including dementia or&#xD;
                  seizures&#xD;
&#xD;
               -  Active uncontrolled infection&#xD;
&#xD;
               -  Other serious underlying medical conditions which could impair the ability of the&#xD;
                  patient to participate in the study&#xD;
&#xD;
          -  Concomitant administration of any other experimental drug under investigation, or&#xD;
             concomitant chemotherapy, hormonal therapy, or immunotherapy&#xD;
&#xD;
          -  concomitant drug medication; The following drugs cause drug interaction with S-1.&#xD;
&#xD;
             i. Warfarin, phenprocoumon: increase bleeding tendency ii. Increase blood&#xD;
             concentration of phenytoin iii. sorivudine: inhibit DPD -&gt; increase toxicity according&#xD;
             to fluoropyrimidine iv. allopurinol : decrease activity of S-1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baek-Yeol Ryoo, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea Institute of Radiological and Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Baek-Yeol Ryoo, M.D., Ph.D.</last_name>
    <phone>+82-2-970-1208</phone>
    <email>ryooby@kcch.re.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hye Jin Kang, M.D.</last_name>
    <phone>+82-2-970-1289</phone>
    <email>hyejin@kcch.re.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Hwasun-gun</city>
        <state>Jeolanam-do</state>
        <zip>519-809</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang Hee Cho, M.D., Ph.D.</last_name>
      <phone>+82-61-379-7633</phone>
      <email>sh115@chollian.net</email>
    </contact>
    <investigator>
      <last_name>Sang Hee Cho, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <state>Jeonbuk</state>
        <zip>561-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eun Kee Song, M.D.</last_name>
      <phone>+82-63-250-1245</phone>
      <email>eksong@chonbuk.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Eun Kee Song, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inha University hospital</name>
      <address>
        <city>Inchon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Moon Hee Lee, M.D., Ph.D.</last_name>
      <phone>+82-32-890-2583</phone>
      <email>moonhlmd@inha.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Moon Hee Lee, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>110-746</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Seung Sei Lee, M.D., Ph.D.</last_name>
      <phone>+82-2-2001-2084</phone>
      <email>llssss.lee@samsung.com</email>
    </contact>
    <investigator>
      <last_name>Seung Sei Lee, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Suk Joong Oh, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kwon Choi, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yonsei Cancer Center</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyun Cheol Chung, M.D., Ph.D.</last_name>
      <phone>+82-2-2228-8132</phone>
      <email>unchung8@yumc.yonsei.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Hyun Cheol Chung, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sun Young Rha, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hei-Cheul Jeung, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul Veterans Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>134-791</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bong-Seog Kim, M.D., Ph.D.</last_name>
      <phone>+82-2-2225-1319</phone>
      <email>seog@e-bohun.or.kr</email>
    </contact>
    <investigator>
      <last_name>Bong-Seog Kim, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea Institute of radiological and Medical Sciences</name>
      <address>
        <city>Seoul</city>
        <zip>139-706</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baek-Yeol Ryoo, M.D., Ph.D.</last_name>
      <phone>+82-2-970-1208</phone>
      <email>ryooby@kcch.re.kr</email>
    </contact>
    <investigator>
      <last_name>Baek-Yeol Ryoo, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sung Hyun Yang, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hye Jin Kang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Im Il Nah, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2006</verification_date>
  <study_first_submitted>June 22, 2006</study_first_submitted>
  <study_first_submitted_qc>June 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2006</study_first_posted>
  <last_update_submitted>May 25, 2010</last_update_submitted>
  <last_update_submitted_qc>May 25, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2010</last_update_posted>
  <responsible_party>
    <name_title>Baek-Yeol Ryoo</name_title>
    <organization>Korea Cancer Center Hospital</organization>
  </responsible_party>
  <keyword>advanced gastric cancer</keyword>
  <keyword>First-line therapy</keyword>
  <keyword>S-1</keyword>
  <keyword>irinotecan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

